Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - TME Pharma NV - TME Pharma publishes its annual financial results and annual report
TME Pharma publishes its annual financial results and annual report
GlobeNewswire

TME Pharma publishes its annual financial results and annual report Berlin, Germany, April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of…

marketwatch.com - Avalyn Pharma Upsized IPO Priced at Top of Expectations
Avalyn Pharma Upsized IPO Priced at Top of Expectations
MarketWatch

Shares of Avalyn Pharma are set to make their trading debut Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the high end of expectations, raising $300 million. Avalyn late Wednesday said…

rediff.com - Text Feed - Ex-Pharma Staff Booked For Fraudulent Government Tenders
Ex-Pharma Staff Booked For Fraudulent Government Tenders
Rediff.com

Two former employees of a Delhi-based pharmaceutical firm have been booked for allegedly cheating and forging documents to fraudulently secure government tenders, including supplies to Army hospitals. Two former employees of a Delhi-based…

globenewswire.com - Zealand Pharma - Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
GlobeNewswire

Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL)…

swissinfo.ch - swissinfo.ch - Swiss pharma firm Novartis plans seventh US plant
Swiss pharma firm Novartis plans seventh US plant
www.swissinfo.ch

The new plant will be dedicated to the production of active pharmaceutical ingredients for solid formulations (tablets, capsules) as well as for RNA-based therapies, the Basel-based pharmaceutical group said in a press release on Thursday. The…

newswire.ca - Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
CNW

STAMFORD, Conn., April 30, 2026 /CNW/ -- Curaleaf Holdings, Inc (TSX: CURA) (OTCQX: CURLF) ('Curaleaf' or the 'Company'), a leading international provider of consumer products in cannabis, has completed the buyout of the remaining 45% stake not…

seekingalpha.com - SA Transcripts - Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Seeking Alpha

Hello. This is Paul Kuntz with RedChip Companies. I want to thank everyone for joining us for what promises to be an exciting session with Lantern Pharma. Today's session is centered around a live real-time demonstration of withZeta.ai, Lantern…

seekingalpha.com - Edmund Ingham - Eli Lilly: Stellar Q1 Earnings Put Pharma In Class Of Its Own, It's Ok To Buy Today (LLY)
Eli Lilly: Stellar Q1 Earnings Put Pharma In Class Of Its Own, It's Ok To Buy Today (LLY)
Seeking Alpha

Eli Lilly (LLY) delivered stellar Q1 2026 revenues of $19.8bn (+56% YoY) and EPS of $8.26 (+170% YoY), raising full-year guidance to $83.5bn at the midpoint. Lilly's growth is powered by the GLP-1 drugs Zepbound and Mounjaro, which now comprise 65%…

newswire.ca - Groupe LSL PHARMA INC. - LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS
LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS
CNW

BOUCHERVILLE, QC, April 30, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (the 'Corporation' or 'LSL Pharma '), a Canadian integrated pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended…

fool.com - Adria Cimino - Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
The Motley Fool

Dividend stocks may be a valuable element in your investing toolkit. This is because, no matter what the overall market is doing, they offer income that's pretty much guaranteed -- particularly if you choose a company with a long history of…

thehindubusinessline.com - Broker's Call: Mankind Pharma (Buy)
Broker's Call: Mankind Pharma (Buy)
BusinessLine

Mankind Pharma's domestic formulation (DF) business is witnessing a healthy revival, with March 2026 growth at 11.5 per cent year on year vs. IPM growth at 10.6 per cent, driven by chronic therapies (cardiac up about 20 per cent/anti-diabetic up…

seekingalpha.com - Dividend Power - West Pharmaceutical: Multiple Growth Drivers Are A Tailwind (NYSE:WST)
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind (NYSE:WST)
Seeking Alpha

West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a…

thehindubusinessline.com - Indian firms boost global acquisitions to $17.3 billion led by Sun Pharma deal
Indian firms boost global acquisitions to $17.3 billion led by Sun Pharma deal
BusinessLine

Sun Pharma's recent big-ticket acquisition of US-based Organon has put the spotlight on Indian companies increasingly making global acquisitions to gain market access and enhance capabilities. There have been more than 70 acquisitions of…

pehub.com - Iris Dorbian - 3 Boomerang-backed Pinnaql snaps up Pharma Resource Group
3 Boomerang-backed Pinnaql snaps up Pharma Resource Group
PE Hub

A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.

thehindubusinessline.com - Bain Capital sells nearly 1% stake in Emcure Pharma for ₹289 crore
Bain Capital sells nearly 1% stake in Emcure Pharma for ₹289 crore
BusinessLine

Global investment firm Bain Capital has divested a nearly 1 per cent stake in Emcure Pharmaceuticals for over ₹289 crore through open market transactions, according to block deal data on the NSE. Following the stake sale, shares of Emcure…

Receive a Daily briefing on Pharma Industry News

Get Started